Nicolas Aznar is a researcher in cancer biology at CNRS and a group leader at the Tissue Biology and Therapeutic Engineering Laboratory (LBTI) in Lyon (France).

Abstract
Stem cells (SCs) and their direct derived organoids offer promising perspectives in regenerative medicine as a source of healthy cells in order to replace their impaired counterparts within a given tissue. Furthermore, cancer-derived organoid culture offers promising perspectives in disease modeling and cancer stem cells (CSCs) studies known to drive tumor initiation, metastatic dissemination, drug resistance, and patients’ relapse. Indeed, high SC signature scores statistically associate with a high risk of tumor relapse in colorectal cancer (CRC) patients. Therefore, the characterization of mechanisms maintaining stem cell phenotypes is crucial for understanding the SC biology in normal and cancerous tissues and for developing new therapeutic approaches to target them.
We have developed a unique and innovative 3D cell culture device (STEADY STEM Technology) improving intestinal organoids / SCs culture quality and allowing the characterization of the gene landscape and regulatory signaling pathways. Leaning on this technology, we take today advantage of our unique technology and cultivate tumor organoids to (1) improve CRC modelling and (2) assess therapeutic drug response for a given patient paving the way for more efficient therapeutic drug screening and personalized medicine

Séminaire le vendredi 17/01/2025 en salle Druet à 13h30
Diffusion en TEAMS